Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from to Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock TOVX NYSE A ...

Corporate Overview December 2022 Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the potential of VCN-01 and its ability to overcome key oncolytic vi ...

Theriva Biologics (NYSE:TOVX) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive and Chief Financial Officer Manel Cascalló - General Director, Theriva Biologics Europe Frank Tufaro - Chief Operating Officer Vince Wacher - Head, Corporate and Product Development Conference Call Participants Jim Molloy - Alliance Global Partners Operator Good day and welcome to the Theriva Biologics formerly Synthetic Bio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-12584 THERIVA BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevad ...

Synthetic Biologics, Inc. (SYN) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Chris Calabrese - Investor Relations Steven Shallcross - Chief Executive & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Laura Suriel - Alliance Global Partners Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Synthetic Biologics' Second Quarter 2022 Earnings Call. Today's conference is being recorded. And ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada 1 ...

Synthetic Biologics, Inc. (SYN) Q1 2022 Earnings Conference Call May 16, 2022 9:00 AM ET Company Participants Dean Schwartz - LifeSci Advisors, IR Steven Shallcross - CEO and CFO Manel Cascallo - General Director of VCN & European Operations Conference Call Participants Jim Molloy - Alliance Global Partners Leland Gershell - Oppenheimer Operator Greetings, and welcome to Synthetic Biologics' First Quarter 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. A question-and- ...

For the transition period from ____________ to ____________ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact name of Registrant as Specified in Its Charter) Nevada ...

Synthetic Biologics, Inc. (SYN) Q4 2021 Earnings Conference Call March 16, 2022 4:30 PM ET CompanyParticipants Chris Calabrese - LifeSci Advisors, IR Steven Shallcross - Chief Executive Officer & Chief Financial Officer Manel Cascallo - General Director of VCN & European Operations Frank Tufaro - Head of Operations of VCN Conference Call Participants Jim Molloy - Alliance Global Partners Jason McCarthy - Maxim Group Michael Okunewitch - Maxim Group Operator Greetings and welcome to the Synthetic Biologics F ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from to Commission File Number: 001-12584 SYNTHETIC BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 13-3808303 (State or Other Jurisdiction of ...